在低中收入国家引入FDG PET/CT引导的同步放化疗治疗III期NSCLC:IAEA PERTAIN试验初步结果
PERTAIN研究评估在低中收入国家引入FDG PET/CT引导的同步放化疗(辅以培训和质控)对III期NSCLC患者总生存(OS)和无进展生存(PFS)的影响。初步中期分析显示,前瞻性队列(128例)相比回顾性队列(230例)OS显著延长(23 vs 14个月,p=0.012),PFS也显著延长(17 vs 11个月,p=0.012)。
要点
- FDG PET/CT引导的同步放化疗可显著改善低中收入国家III期NSCLC患者的OS和PFS。
- 前瞻性队列中位OS为23个月,回顾性队列为14个月(p=0.012)。
- 前瞻性队列中位PFS为17个月,回顾性队列为11个月(p=0.012)。
核心结论
- 在低中收入国家引入FDG PET/CT引导的同步放化疗,可显著改善III期NSCLC患者的OS和PFS。
研究设计与样本
- 研究纳入7个国家9个医学中心的III期NSCLC患者。
- 回顾性队列(2010年1月至2014年7月)按当地实践管理,FDG PET/CT仅可选用于分期(不用于靶区勾画),后续行序贯或同步放化疗。
- 前瞻性队列(2015年8月至2018年10月)按研究方案治疗,包括治疗体位FDG PET/CT用于分期和多模态靶区勾画,随后由接受方案特异性靶区勾画培训且进行质控的专家实施同步放化疗。
- 采用Kaplan-Meier法评估回顾性和前瞻性队列的OS和PFS。
主要发现
- 2018年11月进行计划中期分析,回顾性队列230例(中位随访14个月),前瞻性队列128例(其中69例随访至少1年)。
- 前瞻性队列OS显著长于回顾性队列(23 vs 14个月,p=0.012)。
- 前瞻性队列中位PFS显著长于回顾性队列(17 vs 11个月,p=0.012)。
关键数值与推荐
- 制定了FDG PET/CT图像采集和靶区勾画指南并发表。
- 所有参与PERTAIN研究的专家在2014年6月至2016年5月期间接受培训。
- 使用的PET/CT扫描仪获得EARL认证。
临床怎么用
- 在低中收入国家,对III期NSCLC患者可采用FDG PET/CT引导的同步放化疗,并辅以培训和质控。
- FDG PET/CT不仅用于分期,还可用于治疗体位的靶区勾画。
局限性
- 本文为计划中期分析的初步结果,最终研究结果基于完整数据预计2020年公布。
- 前瞻性队列中仅69例随访至少1年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with stage III non-small-cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT) in low- and middle-income countries (LMIC) continue to have a poor prognosis. It is known that FDG PET/CT improves staging, treatment selection and target volume delineation (TVD), and although its use has grown rapidly, it is still not widely available in LMIC. CRT is often used as sequential treatment, but is known to be more effective when given concurrently. The aim of the PERTAIN study was to assess the impact of introducing FDG PET/CT-guided concurrent CRT, supported by training and quality control (QC), on the overall survival (OS) and progression-free survival (PFS) of patients with stage III NSCLC. METHODS: The study included patients with stage III NSCLC from nine medical centres in seven countries. A retrospective cohort was managed according to local practices between January 2010 and July 2014, which involved only optional diagnostic FDG PET/CT for staging (not for TVD), followed by sequential or concurrent CRT. A prospective cohort between August 2015 and October 2018 was treated according to the study protocol including FDG PET/CT in treatment position for staging and multimodal TVD followed by concurrent CRT by specialists trained in protocol-specific TVD and with TVD QC. Kaplan-Meier analysis was used to assess OS and PFS in the retrospective and prospective cohorts. RESULTS: Guidelines for FDG PET/CT image acquisition and TVD were developed and published. All specialists involved in the PERTAIN study received training between June 2014 and May 2016. The PET/CT scanners used received EARL accreditation. In November 2018 a planned interim analysis was performed including 230 patients in the retrospective cohort with a median follow-up of 14 months and 128 patients in the prospective cohort, of whom 69 had a follow-up of at least 1 year. Using the Kaplan-Meier method, OS was significantly longer in the prospective cohort than in the retrospective cohort (23 vs. 14 months, p = 0.012). In addition, median PFS was significantly longer in the prospective cohort than in the retrospective cohort (17 vs. 11 months, p = 0.012). CONCLUSION: In the PERTAIN study, the preliminary results indicate that introducing FDG PET/CT-guided concurrent CRT for patients with stage III NSCLC in LMIC resulted in a significant improvement in OS and PFS. The final study results based on complete data are expected in 2020.
引用
- Konert T, Vogel WV, Paez D, et al. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial. Eur J Nucl Med Mol Imaging. 2019. PMID: 31367906. doi:10.1007/s00259-019-04421-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。